Related Experiment Video

Updated: May 20, 2025

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
07:28

Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation

Published on: October 11, 2024

284

Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation

Justin P Rosenheck1, Kashika Goyal1, Tara Fallah2

  • 1Ohio State University, Department of Internal Medicine, Division of Pulmonary Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.

JHLT Open
|March 27, 2025
PubMed

Keywords:
Group 1Lung TransplantPAHPulmonary Arterial HypertensionSotatercept

More Related Videos

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

793
Rat Heterotopic Abdominal Heart/Single-lung Transplantation in a Volume-loaded Configuration06:16

Rat Heterotopic Abdominal Heart/Single-lung Transplantation in a Volume-loaded Configuration

Published on: May 29, 2015

8.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139